CG Oncology, Inc. Common stock Earnings Dividend

CG Oncology, Inc. Common stock’s revenue jumped +Inf% since last year same period to $1.16Mn in the Q2 2026. On a quarterly growth basis, CG Oncology, Inc. Common stock has generated 6.83% jump in its revenue since last 3-months.

CG Oncology, Inc. Common stock’s net profit fell -90.84% since last year same period to $-79.06Mn in the Q2 2026. On a quarterly growth basis, CG Oncology, Inc. Common stock has generated -31.32% fall in its net profits since last 3-months.

CG Oncology, Inc. Common stock’s net profit margin jumped NaN% since last year same period to -6832.84% in the Q2 2026. On a quarterly growth basis, CG Oncology, Inc. Common stock has generated -22.92% fall in its net profit margins since last 3-months.

CG Oncology, Inc. Common stock’s earning per share (EPS) estimates for the current quarter stand at -0.7 - a -20.69% fall from last quarter’s estimates.

CG Oncology, Inc. Common stock’s earning per share (EPS) estimates for the current year stand at -0.7.

CG Oncology, Inc. Common stock’s earning per share (EPS) fell -66.67% since last year same period to -0.9 in the Q2 2026. This indicates that the CG Oncology, Inc. Common stock has generated -66.67% annual rate of fall in its earning per share (EPS) in the last 4 quarters.